PRECISION BIOSCIENCES INC (DTIL) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$5.80

From 52W high−33.30%

Volume176468.00

Market cap$170.85M

P/E (TTM)—

P/S (TTM)3.8x

Div yield—

Key dataOct 19, 2026

Open

$5.80

From 52W high

−33.30%

Volume

176468.00

Market cap

$170.85M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.2x

P/E (TTM)

—

RSI (14)

41.2

MomentumView details →

1D Return

+7.28%

YTD Return

+45.43%

SummaryUpdated Jun 1, 2026

Precision BioSciences, Inc. (NASDAQ:DTIL) is a clinical-stage biotechnology company founded in 2006 and headquartered in Durham, North Carolina. The company went public in March 2019 and focuses on developing advanced gene editing therapies to treat genetic disorders and cancer. Precision BioSciences operates at the cutting edge of biotechnology, utilizing proprietary gene editing platforms to create both in vivo therapies that work directly within patients' bodies and ex vivo treatments that modify cells outside the body before reintroduction.

Ask drillr about PRECISION BIOSCIENCES INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.2x

EV/Sales

2.5x

P/S (TTM)

3.8x

P/B (TTM)

3.8x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−117.04%

EBITDA Margin

−110.31%

ROE (TTM)

−116.42%

ROA (TTM)

−41.88%

Asset Turnover

0.33x

GrowthView details →

Revenue YoY

+3472.96%

EPS YoY

+69.64%

FCF YoY

+19.32%

Revenue CAGR 3Y

+10.93%

EPS CAGR 3Y

—

EBITDA YoY

+32.59%

MomentumView details →

1D Return

+7.28%

YTD Return

+45.43%

1Y Return

−15.50%

RSI (14)

41.2

vs 50D SMA

−14.32%

vs 200D SMA

−5.66%

Capital & dividendView details →

Debt/Equity

0.62x

Current Ratio

12.82x

Quick Ratio

12.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.26

EPS Surprise

−56.72%

Beats (12Q)

6/12

Next Q EPS Est

−$0.83

Avg Surprise (4Q)

−690.82%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

45.05M

Net Income (TTM)

−52.73M

Op. CF (TTM)

−51.90M

Next earningsNov 2, 2026 →

Latest newsMore news →

PRECISION BIOSCIENCES INC announced that it was selected to deliver a late-breaking oral presentation on PBGENE-HBV at The Liver Meeting 2026.12d ago

Precision BioSciences reported its financial results for the second quarter ended June 30, 2026, and provided a business update on August 6, 2026.75d ago

Similar companies

Whitehawk Therapeutics IncWHWK Oramed Pharmaceuticals Inc.ORMP Yarrow Bioscience IncYARW Eledon Pharmaceuticals, Inc.ELDN NervGen Pharma Corp. Common stockNGEN MediWound Ltd.MDWD Find similar companies →

Latest newsMore news →

PRECISION BIOSCIENCES INC announced that it was selected to deliver a late-breaking oral presentation on PBGENE-HBV at The Liver Meeting 2026.12d ago Precision BioSciences reported its financial results for the second quarter ended June 30, 2026, and provided a business update on August 6, 2026.75d ago